OASMY
Price:
$0.05
Market Cap:
$13.12M
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The c...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2015-10-23
Stock Exchange
PNK
Ticker
OASMY
According to Vivesto AB’s latest financial reports and current stock price. The company's current ROE is -47.38%. This represents a change of 302.20% compared to the average of -11.78% of the last 4 quarters.
The mean historical ROE of Vivesto AB over the last ten years is -44.45%. The current -47.38% ROE has changed 6.57% with respect to the historical average. Over the past ten years (40 quarters), OASMY's ROE was at its highest in in the December 2021 quarter at -0.53%. The ROE was at its lowest in in the December 2023 quarter at -30.74%.
Average
-44.45%
Median
-38.67%
Minimum
-112.86%
Maximum
-1.29%
Discovering the peaks and valleys of Vivesto AB ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.33%
Maximum Annual ROE = -1.29%
Minimum Annual Increase = -97.67%
Minimum Annual ROE = -112.86%
Year | ROE | Change |
---|---|---|
2023 | -65.05% | -42.37% |
2022 | -112.86% | 343.23% |
2021 | -25.46% | 38.39% |
2020 | -18.40% | 1.33% |
2020 | -1.29% | -97.67% |
2019 | -55.26% | 53.49% |
2018 | -36.00% | -33.38% |
2017 | -54.04% | 30.69% |
2016 | -41.35% | 18.66% |
The current ROE of Vivesto AB (OASMY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-67.79%
5-year avg
-44.61%
10-year avg
-44.45%
Vivesto AB’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vivesto AB using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vivesto AB or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Vivesto AB's ROE?
How is the ROE calculated for Vivesto AB (OASMY)?
What is the highest ROE for Vivesto AB (OASMY)?
What is the 3-year average ROE for Vivesto AB (OASMY)?
What is the 5-year average ROE for Vivesto AB (OASMY)?
How does the current ROE for Vivesto AB (OASMY) compare to its historical average?